Bayer HealthCare / Press

Bayer Receives Approval for EYLEA® for the Treatment of Myopic Choroidal Neovascularization in Japan

Bayer HealthCare has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for EYLEA® (aflibercept solution for injection) for the treatment of myopic choroidal neovascularization (myopic CNV). In Japan, pathologic myopia and the associated myopic CNV is the second most common cause of blindness. more      

In Focus

Healthcare News

Photos & Videos

  • Photos

    Photo galleries with topic-related images.

  • TV Footage

    In this section you can find videos for editorial coverage.

Bayer HealthCare Links

Annual report Integrated Annual Report of Bayer AG 2013
RSS Feed
RSS Feed

Copyright © Bayer HealthCare AG